Disease Landscape and Forecast Insights

Over the forecast period (2024-2034), the osteoporosis therapy market is poised for significant growth, driven by an increasing prevalence of postmenopausal osteoporosis and increasing diagnosis…

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

Over the forecast period (2024-2034), the osteoporosis therapy market is poised for significant growth, driven by an increasing prevalence of postmenopausal osteoporosis and increasing diagnosis…

Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…

China accounts for nearly half of the cases of gastroesophageal cancer in the world, and its incidence there is expected to increase due to urbanization and an aging population. Current treatment…

Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…

Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…

The breast cancer therapy market is one of the most dynamic markets in the oncology space in mainland China. Several new and emerging therapies are set to be approved for select subpopulations;…

Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: TNF-alpha inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Johnson & Johnson…

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: TNF-alpha inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira, Johnson & Johnson…

The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, and immunotherapies such as Roche’…